m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00705)
Name
MS436
Status
Investigative
Structure
Formula
C18H17N5O3S
InChI
1S/C18H17N5O3S/c1-12-10-16(15(19)11-17(12)24)22-21-13-5-7-14(8-6-13)27(25,26)23-18-4-2-3-9-20-18/h2-11,24H,19H2,1H3,(H,20,23)
InChIKey
DZTGIRNXWSZBIM-UHFFFAOYSA-N
PubChem CID
135566899
TTD Drug ID
D09HBR
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Bromodomain-containing protein 4 (BRD4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Bromodomain-containing protein 4 (BRD4) is a therapeutic target for MS436. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MS436 through regulating the expression of Bromodomain-containing protein 4 (BRD4). [1], [2]
References
Ref 1 mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 Sep;561(7724):556-560. doi: 10.1038/s41586-018-0538-8. Epub 2018 Sep 19.
Ref 2 Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2013 Jul 16;4(9):835-40. doi: 10.1021/ml4001485. eCollection 2013 Sep 12.